Optical Prism September 2019 | Page 33

Special Feature contact lens combined with an antihistamine. We’ll continue to progress this pioneering work in hopes of one day offering a new solution. Q. In countries like Canada, what are the common causes of ocular allergies? A. Common causes are quite consistent across the world. Ocular allergy can be seasonal or perennial and occur when people are exposed to allergens such as tree or grass pollen, pet dander or dust. Some of the worst allergy-inducers in Canada more specifically are related to trees that shed airborne pollen, including ash, alder, birch, cedar, elm, oak and walnut, but these along with variable weeds can vary based on the part of the country you may be in. included 244 patients and used the conjunctival allergen challenge model (Ora-CAC®) as a replicable measure to assess the efficacy of the investigational contact lens. Reduction in ocular itching was reported as quickly as 15 minutes after lens insertion and lasted for the full duration of the study evaluation period, which was 12 hours. overall) with the majority being mild and not considered study related. Additionally, there were no discontinuations from study treatment based on any ocular adverse events. Secondary endpoints in the trials evaluated the reduction in eye redness, but did not demonstrate a clinically significant reduction in people wearing the antihistamine-releasing lenses. Both the antihistamine-releasing contact lenses and the control lenses demonstrated a low rate ocular adverse events (4.9% A. We are encouraged about the recent data publication and results and are continuing to develop the investigational antihistamine- releasing contact lens as a potential new category of contact lenses. Q. What are the next steps for the testing/trial stage for this proposed product? We continue to progress this pioneering work in hopes of one day offering a new solution. OP Q. What were the highlights from the latest trials for J&J's investigational antihistamine- releasing contact lens? A. The Phase 3 data published in Cornea showed both a clinically and statistically meaningful reduction in itchy, allergy eyes with the antihistamine-releasing contact lenses compared to non-medicated lenses. These large-scale studies represent the first time that contact lens-based technology has shown the potential to correct vision and reduce the occurrence of eye itch from allergies. The two multi-center, randomized, placebo-controlled studies Optical Prism | September 2019 33